CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 19 enrolled
Drug / intervention
ATEZOLIZUMAB +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03417544
NCT03417544Phase 2Active
CompareCT.gov

A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer

Nancy Lin, MD·interventional·Posted Jan 31, 2018·Updated Apr 27, 2026

In Brief

A Phase 2 clinical trial evaluating ATEZOLIZUMAB, PERTUZUMAB, and 1 other intervention for HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases. Active but no longer recruiting, targeting 19 participants across 2 sites.

Detailed Summary

This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2ActiveOverdue
201820192020202120222023202420252026
First PostedJan 31, 2018
Enrollment StartMay 21, 2018
Primary CompletionMay 20, 2020
Study CompletionMay 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.4 years ago

Interventions

ATEZOLIZUMABdrug

(IV) every 3 weeks

PERTUZUMABdrug

Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV

TRASTUZUMABdrug

Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks